ÂÜÀòÂÒÂ×

Alex Lugovskoy has over fifteen years of experience in the biotech industry, with a focus on drug development. Alex is currently Scientific Advisor at Manifold Bio, and previously served as Chief Operating Officer at Dragonfly Therapeutics, Inc. and Chief Development Officer at Morphic Therapeutic.

Lugovskoy began their career in the biotech industry as a research scientist. Alex then transitioned into management, first as Director of Regulatory Affairs and Quality Assurance at Avila Therapeutics, Inc., and then as Vice President of Technical Operations at Infinity Pharmaceuticals, Inc. In these roles, they were responsible for overseeing the development and implementation of quality systems and compliance with cGMP regulations.

In 2016, Lugovskoy became Chief Development Officer at Morphic Therapeutic. In this role, they were responsible for drug development into first-in-human clinical studies. Alex also built and led the Safety Assessment, Technical Operations, Regulatory Affairs, Quality Assurance, Program and Alliance Management, Information Technology, Data Science, and Business Development teams. During their time at Morphic Therapeutic, they forged research and development collaborations with AbbVie and Janssen.

In 2020, Lugovskoy left Morphic Therapeutic to become Chief Operating Officer at Dragonfly Therapeutics, Inc. In this role, they led a 100+ strong R&D organization comprising Biology, Biologics, CMC, Quality, Toxicology, Information Technology, Data Science, Operations and Program and Alliance Management. Alex also expanded the company's focus into autoimmunity (DF5300) while delivering three programs to opt-in decisions by BMS, Merck and AbbVie.

Lugovskoy has a proven track record of success in the biotech industry. Their experience in both research and management makes him an asset to any organization.

Alex Lugovskoy has a Ph.D. in Biophysics from Harvard University, an Advanced Certificate for Executives in Management, Innovation and Technology from the MIT Sloan School of Management, an M.S. in Chemistry from the Massachusetts Institute of Technology, and a B.S./M.S. in Math and Physics/Molecular Biophysics from the Moscow Institute of Physics and Technology (State University). Alex also has a B.S. in Electrical Engineering from Ryazan State Radiotechnical University (former Academy) and a certification from the MIT Sloan School of Management in Artificial Intelligence: Implications for Business Strategy.